These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32462419)

  • 21. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.
    Gašperšič J; Videtič Paska A
    Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
    Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between the peripartum maternal and fetal telomere lengths and mitochondrial DNA copy numbers and preeclampsia: a prospective case-control study.
    Zhang R; Du J; Xiao Z; Jiang Y; Jin L; Weng Q
    BMC Pregnancy Childbirth; 2022 Jun; 22(1):483. PubMed ID: 35698093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients.
    Mondelo-Macía P; Rodríguez-López C; Valiña L; Aguín S; León-Mateos L; García-González J; Abalo A; Rapado-González O; Suárez-Cunqueiro M; Díaz-Lagares A; Curiel T; Calabuig-Fariñas S; Azkárate A; Obrador-Hevia A; Abdulkader I; Muinelo-Romay L; Diaz-Peña R; López-López R
    Cells; 2020 Feb; 9(2):. PubMed ID: 32102486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combinatory Analysis of Cell-free and Circulating Tumor Cell DNAs Provides More Variants for Cancer Treatment.
    Lee SY; Chae DK; An J; Yoo S; Jung S; Chae CH; Bhak J; Kim BC; Cho DH
    Anticancer Res; 2019 Dec; 39(12):6595-6602. PubMed ID: 31810925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of cfDNA and long fragment DNA in patients with breast cancer.
    Xu H; Liu G
    Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):186-189. PubMed ID: 33287940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping.
    Kambayashi S; Ono N; Tone T; Baba K; Okuda M
    Vet Comp Oncol; 2024 Jun; 22(2):303-309. PubMed ID: 38287199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced detection of cell-free DNA (cfDNA) enables its use as a reliable biomarker for diagnosis and prognosis of gastric cancer.
    Bu J; Lee TH; Jeong WJ; Poellmann MJ; Mudd K; Eun HS; Liu EW; Hong S; Hyun SH
    PLoS One; 2020; 15(12):e0242145. PubMed ID: 33264292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients.
    Jarmuzek P; Wawrzyniak-Gramacka E; Morawin B; Tylutka A; Zembron-Lacny A
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of promoter methylation of MCPH1 gene in circulating cell-free DNA of brain tumor patients.
    Ghodsi M; Shahmohammadi M; Modarressi MH; Karami F
    Exp Brain Res; 2020 Sep; 238(9):1903-1909. PubMed ID: 32556427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
    Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings.
    Liew PL; Huang RL; Wu TI; Liao CC; Chen CW; Su PH; Wang HC; Weng YC; Lai HC
    Clin Epigenetics; 2019 Nov; 11(1):170. PubMed ID: 31779688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of plasma cell-free DNA levels in dogs with various tumors.
    Tagawa M; Shimbo G; Inokuma H; Miyahara K
    J Vet Diagn Invest; 2019 Nov; 31(6):836-843. PubMed ID: 31585514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
    Miao Y; Fan Y; Zhang L; Ma T; Li R
    Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Heidinger M; Egle D; Piscuoglio S; Navarro-Aguadero MÁ; Sánchez S; Hergueta-Redondo M; Gallardo M; Barrio S; García-Peláez B; Molina-Vila MA; Maggi N; Eller RS; Loesch JM; Alborelli I; Peinado H; Weber W; Weber WP
    Anticancer Res; 2024 Jul; 44(7):2981-2988. PubMed ID: 38925824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.
    Gu Y; Wan C; Qiu J; Cui Y; Jiang T; Zhuang Z
    PLoS One; 2020; 15(2):e0224001. PubMed ID: 32027658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer.
    Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A
    Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.
    Raei M; Heydari K; Tabarestani M; Razavi A; Mirshafiei F; Esmaeily F; Taheri M; Hoseini A; Nazari H; Shamshirian D; Alizadeh-Navaei R
    BMC Cancer; 2024 Jul; 24(1):908. PubMed ID: 39069608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
    Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
    Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.